Aetna Infliximab (Remicade & Biosimilars) prior authorization requirements (2026)
What Aetna generally requires to approve Infliximab (Remicade & Biosimilars) (CPT J1745, Q5103, Q5104, Q5121), for Commercial plans. Yes. Aetna generally requires prior authorization for Infliximab (Remicade & Biosimilars) (CPT J1745, Q5103, Q5104, Q5121).
Medical-necessity criteria Aetna generally applies
Precertification required for all infliximab products. RHEUMATOID ARTHRITIS (prescribed by/with a rheumatologist): biologic-naive patients need a positive biomarker (RF or anti-CCP positive, or tested for RF + anti-CCP + CRP/ESR), failure to reach low disease activity after a 3-month trial of methotrexate titrated to at least 15 mg/week (or another conventional synthetic DMARD), and use in combination with methotrexate or leflunomide unless contraindicated. CROHN'S DISEASE / ULCERATIVE COLITIS: moderately-to-severely active disease. TB SCREENING REQUIRED for all indications: documented negative TST or IGRA within 12 months before initiating in biologic-naive patients; if positive, confirm no active disease and treat latent TB before starting. Maintenance RA dosing 3 mg/kg IV every 8 weeks (up to 10 mg/kg or as often as every 4 weeks); CD/UC induction 5 mg/kg at weeks 0, 2, 6 then every 8 weeks. Reauthorization requires at least 20% improvement from baseline (RA) or documented clinical response/remission (IBD).
Diagnoses that commonly support medical necessity
ICD-10-CM diagnoses frequently associated with medical necessity for Infliximab (Remicade & Biosimilars). Confirm the covered diagnosis list against the current Aetna policy.
Commonly required documentation
- Diagnosis with biomarker results (RA)
- documented conventional-therapy trial and outcome
- documented negative TB test within 12 months
- chart notes supporting moderate-to-severe disease.
Situations to verify before submitting
Aetna may not cover Infliximab (Remicade & Biosimilars) in these situations. Verify against the current policy rather than assuming a denial:
- Concurrent use with another biologic or targeted synthetic drug for the same indication is considered experimental/investigational
- Doses above 5 mg/kg are contraindicated in moderate-to-severe (NYHA class III/IV) heart failure
How to submit
- Method: Aetna precertification (Availity)
- Portal: Availity
Source
Source: Aetna CPB 0341 Infliximab (last review 2026-04-27). Codes J1745, Q5103, Q5104, Q5121. Last verified 2026-06-17.
Frequently asked questions
Does Aetna require prior authorization for Infliximab (Remicade & Biosimilars)?
Yes. Aetna generally requires prior authorization for Infliximab (Remicade & Biosimilars) (CPT J1745, Q5103, Q5104, Q5121).
What does Aetna require to approve Infliximab (Remicade & Biosimilars)?
Precertification required for all infliximab products. RHEUMATOID ARTHRITIS (prescribed by/with a rheumatologist): biologic-naive patients need a positive biomarker (RF or anti-CCP positive, or tested for RF + anti-CCP + CRP/ESR), failure to reach low disease activity after a 3-month trial of methotrexate titrated to at least 15 mg/week (or another conventional synthetic DMARD), and use in combina… Always confirm against the current Aetna policy.
How long does a Aetna prior authorization take?
Turnaround varies by plan and submission method. Check the Aetna portal for current timeframes.
Submitting Infliximab (Remicade & Biosimilars) to Aetna?
Praxigen checks your clinical note against these criteria before you submit and drafts a policy-cited appeal if it is denied. You review and submit; nothing is sent automatically.